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Abstract:  Detection of the toxicity of a candidate compound at an early stage of drug development is an emerging area
of interest.  It is difficult to determine all of the effects of metabolism of a compound using traditional approaches such
as histopathology and serum biochemistry.  The goal of a metabolomics approach is to determine all metabolites in a
living system, with the potential to detect and identify biomarkers involved in toxicity onset.  Here, we summarize the
metabolic fingerprints for detection and identification of metabolic changes and biomarkers related to drug-induced
toxicity using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).  (J Toxicol Pathol 2010; 23:
67–74)
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Introduction
Analysis using the “omics” (transcriptomics,
proteomics and metabolomics) has become widespread in
the post-genomics era, with one objective being the large-
scale quantitative determination of mRNAs, proteins and
metabolites to establish gene function and ascertain the
connectivity within the “omics” hierarchy1.  Metabolomics
can be defined as an attempt to measure all the metabolites
within a cell, tissue or organism with a genetic modification,
in response to a physiological stimulus, or under specific
conditions at a specified time2.  Metabolites are the end-
products of a biological system and changes in metabolites
can therefore be regarded as the final response of an
organism to changes in gene expression.  Genome-wide
expression of genes is amplified gradually through the
hierarchy of the transcriptome, proteome and metabolome.
Changes in the concentrations of enzymes (and the
transcripts that encode them) may have only small effects via
metabolic pathways, but can have substantial effects on the
concentration of metabolic intermediates.  Consequently, the
metabolome may be more sensitive to perturbations
compared with either the transcriptome or proteome3.
The technologies that enable performance of
metabolomics have recently increased in power4.
Transcriptomics and proteomics are based on target
chemical analysis of biopolymers composed of 4 different
nucleotides (transcriptome) or 20 amino acids (proteome).
The chemical similarity of these compounds facilitates high-
throughput analysis.  In contrast, the metabolome has a large
variety of chemical structures and properties, from ionic
inorganic species to hydrophilic carbohydrates, volatile
alcohols and ketones, organic amino and non-amino acids,
hydrophobic lipids, and complex natural products5.  This
complexity makes it difficult to determine the complete
metabolome simultaneously6.  Therefore, it is common to
perform quantitative determination of one or a few
metabolites related to a specific metabolic pathway after
extensive sample preparation and separation from the
sample matrix using chromatographic separation and
sensitive detection, which is refered to as “target analysis”.
The following two metabolomic approaches are common: i)
metabolic profiling to identify and quantify metabolites
related through similar chemistries or metabolic pathways
using chromatographic separation before detection with
minimal metabolite isolation after sampling and ii)
metabolic fingerprinting for rapid global analysis of crude
samples or extracts for classification or screening of samples
without identification and quantification.
The technologies for metabolomics can also be
classified into categories based on detection using mass
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spectrometry (MS), nuclear magnetic resonance (NMR)
spectroscopy, and Fourier transform infrared (FT-IR)
spectroscopy.  The high sensitivity of MS makes it an
important method for measuring metabolites in complex
biosamples.  Gas chromatography (GC) and GC-MS are
used for quantitative metabolic profiling, with GC first used
over 20 years ago for disease diagnosis7.  There has been
rapid growth in metabolomic applications based on GC-MS
for analysis of volatile and thermally stable polar and
nonpolar metabolites, while developments in liquid
chromatography (LC)-MS and capillary electrophoresis
(CE)-MS have broadened the applicability of MS-based
metabolomics.  Tandem MS and accurate mass (time of
flight) methods are normally used to validate the identities of
unknown metabolites.  NMR and FT-IR spectroscopy are
used for structural analysis of compounds, but have
relatively low sensitivity compared with MS.  Nevertheless,
NMR- and FT-IR-based metabolic profiling have been used
successfully in many fields because both methods are highly
quantitative and reproducible.
The utility of metabolomics for toxic evaluation of
compounds with NMR was comprehensively assessed by the
Consortium for Metabonomic Toxicology (COMET), which
was founded by five major pharmaceutical companies and
Imperial College London, U.K.8.  The main objectives of
COMET were to assess and develop methodologies to
generate a metabolomics database using NMR analysis of
rodent urine and blood serum dosed with hepato- and
nephrotoxins for preclinical toxicological screening of
candidate drugs and to build an expert system for prediction
of the site and mechanism of toxicity.  This approach was
used successfully to determine metabolic interspecies
variation between rats and mice dosed with a toxin9.  The
goal of the second COMET project (COMET 2) is to
improve on the knowledge obtained in COMET by detailed
testing of hypotheses in metabolomics using NMR and LC-
MS10.
The discovery of biomarkers is a major objective in
determining the toxicity of drug and identification of toxic
biomarkers through a metabolomics approach is an
emerging area.  There are many reports of potential
biomarkers in administration of a variety of drugs, and
identification of toxicological biomarkers may contribute to
assessment of the mechanisms of toxicity in drug
development.
Metabolic Fingerprinting with FT-ICR MS for 
Biomarker Identification and Toxicity 
Evaluation
Fourier transform ion cyclotron resonance mass
spectrometry (FT-ICR MS) can be used to obtain an ultra-
high resolution (>100,000) mass spectrum in about one
second.  Separation of the metabolites is possible with this
method alone, eliminating the need for time-consuming
chromatography and derivatization.  Identification of
putative metabolites, or the class to which they belong, can
be achieved by determining the elemental composition of the
metabolite based upon the ultra-high mass accuracy11,12.  The
utility of this approach has been demonstrated in
phenotyping of plants, in which the ripening process has
been investigated in strawberries and transgenic mutant
tobacco plants13.  In this review, we summarize our recent
findings for metabolic fingerprints of rat urine using FT-ICR
MS.
Drug-induced phospholipidosis
We used phospholipidosis (PLD), which is a well-
examined drug-induced symptom, to evaluate the utility of
FT-ICR MS for toxicological metabolomics14.  PLD can be
induced by cationic amphiphilic drugs (CADs)15 and is
characterized by an abnormal intracellular accumulation of
phospholipids and multilamellar bodies, as observed by
electron microscopy16.  Amiodarone (AMD), perhexiline,
fluoxetine and gentamicin induce PLD in humans15, and
PLD in animal models has been observed with CADs at
doses far in excess of those used clinically.
Histopathological examinations using light and electron
microscopy have traditionally been used to detect PLD in
drug-treated animals, but these methods are time-consuming
and cannot be performed in humans.
Urine samples from rats treated orally with AMD at 300
mg/kg/day for 3 days were analyzed using an FT-ICR MS
instrument equipped with a 7.0-T actively shielded
superconducting magnet (IonSpec, Lake Forest, CA,
U.S.A.).  Higher intensity signals at m/z 192.06676 and
212.00239 and a lower intensity signal at m/z 178.05101
were observed in the AMD-treated urine samples compared
to the controls (Fig. 1).  A loading plot revealed that these
metabolites contributed to discrimination among the
samples.  The ions at m/z 178.05101, 192.06676 and
212.00239 were identified as hippurate (HA),
phenylacetylglycine (PAG) and indican (IDN), respectively.
PAG is the end product of phenylalanine metabolism in
rodents17 and has been reported as a biomarker using NMR18
and LC-MS19.  Elevation of urinary PAG after treatment
with a CAD such as AMD that causes phospholipid
accumulation may be related to changes in gut flora or the
integrity of the intestine20.  IDN is derived from the action of
intestinal bacteria containing tryptophanase, which converts
tryptophan to indole.  Indole is then absorbed and conjugated
in the liver to form IDN, which was also shown to be a
urinary PLD biomarker on the loading plot.  AMD treatment
has been linked to changes in the gut or the integrity of the
intestine that result in increased absorption of the PAG
precursor, phenylacetate (PA), leading to an elevated level of
urinary PAG20.  A decrease in urinary HA levels has been
detected in urinary metabolic fingerprinting for AMD-
induced PLD using NMR21, consistent with the findings
from FT-ICR MS.  The decrease in urinary HA has been
proposed as a nonspecific marker of toxicity that reflects a
complex combination of factors such as dietary intake and
gut microbial metabolism22,23.  These results show that
urinary metabolic fingerprinting with FT-ICR MS can beHasegawa, Ide, Kuwamura et al. 69
used to detect potent biomarkers for AMD-induced PLD and
suggest that this method is applicable to toxicological
assessment of compounds.
Drug-induced hepatotoxicity
The liver is the organ that is most exposed to drugs,
with the concentration in the liver often being higher than the
peak plasma concentration.  The liver is also the major site
for metabolism of xenobiotics that can lead to formation of
active metabolites.  Thus, evaluation of liver toxicity is
particularly important in development of new therapeutic
compounds.  Here, we describe the urinary metabolic
fingerprint of rat urine following treatment with two
hepatotoxins, thioacetamide (TAA) and α-
naphthylisothiocyanate (ANIT), to investigate the
relationship between histopathology and serum
biochemistry and to search for possible biomarkers involved
in hepatic toxicity24,25.
TAA-induced acute hepatic injury in rats:  Rats were
administered a single intraperitoneal injection of TAA (Day
0) at a dose of 300 mg/kg body weight.  ALT and AST in
serum both increased on Day 1, indicating that hepatocyte
injury had occurred.  These values decreased on Day 3 and
were almost at pre-dose levels on Day 5.
Histopathologically, TAA-induced centrilobular necrosis of
hepatocytes accompanied by a small amount of mononuclear
cell infiltration was observed on Day 1 (Fig. 2b).  Hepatocyte
injury and infiltration of mononuclear cells became more
prominent in the centrilobular area on Day 3 (Fig. 2c), and
the majority of infiltrating cells were reactive with anti-ED1
(Fig. 2d).  Hepatocyte injury and cell infiltration had almost
completely disappeared on Days 5 (Fig. 2e) and 7 (Fig. 2f).
In negative ion spectra, the intensities of the ions at m/z
178.05038, 191.01967, 212.00226, 242.01320 and
258.99494 decreased on Days 1 and 3 compared to the pre-
dose intensities (Fig. 3A).  In positive ion spectra, the
intensity of the ion at m/z 401.20737 increased on Day 1, that
at m/z 266.05390 increased on Day 3, and that at m/z
429.23882 decreased on Day 1 compared to the pre-dose
intensities (Fig. 4A).  The PCA scores plot showed that the
negative ion compositions of TAA-treated rat urine samples
on Days 1 and 3 differed from the pre-dose compositions,
with the largest change seen on Day 1 (Fig. 3B).  By Day 5,
the composition was close to that in pre-dose samples (Fig.
3B).  ALT and AST are well-known serum biochemical
markers for hepatocyte injury and increased levels of these
markers were seen on Day 1, with subsequent decreases on
Day 3.  The shift on the PCA scores plot for the negative ions
showed a similar pattern for changes of ALT and AST.  The
positive ion compositions of the TAA-treated rat urine
samples on Days 1 and 3 also differed from those in the pre-
dose samples, but were similar to the pre-dose compositions
on Days 5 and 7 (Fig. 4B).  Histopathologically, hepatocyte
injury accompanied by cell infiltration was seen on Day 1
and these lesions were more prominent on Day 3.  These
results indicate that the changes in positive ion compositions
might reflect the histopathological changes.
The loading plot suggested that the negative ions at m/z
178.05038, 191.01967, 192.06628, 212.00226, 220.14673,
242.01320, 258.99494 and 303.06000 and the positive ions
at m/z 266.05390, 401.20737 and 429.23882 were potential
biomarkers for acute hepatic injury.  The ions at m/z
178.05038, 192.06628, 212.00226 and 242.01320 were
identified as HA, PAG, IDN and 3-methyldioxyindole
sulfate, respectively.  The alterations of HA and IDN
depended on administration of TAA, which caused changes
in the distribution of the bacterial flora.  Decrease of an ion
at m/z 242 has been reported in urinary metabolic
fingerprinting in ANIT-induced intrahepatic cholestasis
using LC-MS26, and this ion may be due to 3-
methyldioxyindole sulfate.  Therefore, these findings
suggest that alteration of urinary 3-methyldioxyindole
sulfate may correlate with hepatotoxicity.
The positive ion at m/z 266.05390 has the empirical
formula [C9H13N3O4K]+ (calculated [M+K]+ =266.05377,
Δm/z 0.00013).  The best candidate for this ion in the
compound library was the potassium ion (K+) adduct of
deoxycytidine (dCyt).  MS/MS analysis of m/z 266.05390 in
TAA-treated rat urine gave rise to an ion at m/z 150.0 that
Fig. 1. (A) FT-ICR MS spectrum and (B) loading plot for
amiodarone-treated rats urine.  (A) Pre-dose (a) and 24 hours
after final dosing (b).  The intensity of the ions at m/z
192.06676 and 212.00239 increased and that for the ion at m/z
178.05101 decreased at 24 hours after final dosing compared
wtih the pre-dose levels.  (B) The loading plot revealed that the
metabolites causing PCA exhibited m/z 178.05101, 192.06676
and 212.00239.70 Metabolomics in Toxicological Assessment
Fig. 2. Histopathological examination of the liver in thioacetamide-treated rats.  (a) Normal histology of the control rat liver; HE stain, bar=60 μm.
(b) Hepatocyte injury and infiltration of a few mononuclear cells in the centrilobular area of a treated rat on Day 1; HE stain, bar=60 μm.
(c) More prominent hepatocyte injury and cell infiltration in the centrilobular area on Day 3; HE stain, bar=60 μm.  (d) The majority of
infiltrated cells showed a positive reaction with ED1 (a rat macrophage specific antibody) on Day 3; immunohistochemistry counterstained
with hematoxylin, bar=60 μm.  (e) Injured hepatocytes and cell reactions disappeared in the affected centrilubular area on Day 5; HE stain,
bar=60 μm.  (f) The affected areas disappeared and recovered the features of the control liver on Day 7; HE stain, bar=60 μm.Hasegawa, Ide, Kuwamura et al. 71
resulted from loss of deoxyribose (–116), and the MS/MS
spectrum of m/z 266.05390 in dCyt-spiked urine was
identical to that for the TAA-treated sample.  These data are
consistent with the hypothesis that m/z 266.05390 in the
TAA-treated urine was the K+ adduct of dCyt.  Phagocytosis
of cell debris by macrophages leads to release of dCyt from
these cells in vitro, and normal rat tissues including the liver
and kidney have no dCyt deaminase activity for conversion
of dCyt to deoxyuridine27.  An increased number of
macrophages were seen on Days 1 and 3 in TAA-injected
rats, in parallel with development of hepatocyte injury, and
therefore macrophage infiltration may be responsible for the
occurrence of dCyt in the urine on Days 1 and 3.  The
majority of macrophages in the injured liver were reactive
with ED1.  Antigens recognized by ED1 occur on the
membranes of cytoplasmic granules, and especially on
phagolysosomes of macrophages, and the degree of ED1
expression depends on the phagocytic activity27.  The
increased number of ED1-reactive macrophages on Days 1
and 3 reflects increased debris from injured hepatocytes.  A
significant amount of dCyt released from infiltrated
macrophages was excreted in urine on Day 3, indicating a
close relationship between hepatic macrophage infiltration
and the appearance of dCyt in urine after TAA
Fig. 3. (A) FT-ICR MS spectrum and (B) PCA scores for
FT-ICR MS urinary profiles of thioacetamide-
treated rats recorded in negative ion mode.  (A)
Pre-dose (a), Day 1 (b), Day 3 (c) and Day 5 (d).
The intensities of the ions at m/z 178.05038,
191.01967, 212.00226, 242.01320 and 258.99494
decreased on Days 1 and 3 compared to the pre-
dose intensities.  (B) Pre-dose ( ), Day 1 ( ),
Day 3 ( ) and Day 5 ( ).  The PCA scores show
that the negative ion compositions of samples on
Days 1 and 3 differed from the pre-dose
composition.  The composition on Day 5 was
similar to the pre-dose composition.72 Metabolomics in Toxicological Assessment
administration.
ANIT-induced intrahepatic cholestasis in rats:  Rats
were administered a single oral injection of ANIT (Day 0) at
a dose of 100 mg/kg body weight.  ALT and AST in serum
increased on Day 1, and these increases were more
pronounced on Day 2.  Total bilirubin (TBIL) was markedly
increased on Day 2, and a lesser increase in alkaline
phosphatase (ALP) was also observed.  These levels then
decreased on Day 4.  In the ANIT-treated rats, bile duct
degeneration and necrosis accompanied by peribiliary
infiltration and edema of neutrophils, and bile duct
obstruction by degenerative epithelium were seen on Day 1.
On Day 2, regenerative bile ducts with edema and
inflammation around portal tracts, and bile duct proliferation
were observed.  Degenerative vacuolation and single cell
necrosis of hepatocytes were evident on Days 1 and 2.  Bile
duct proliferation and increased mitosis of hepatocytes were
observed on Day 4.
In negative ion spectra, the intensities of the ions at m/z
178.05168 and m/z 192.06730 decreased at 0–48 h and 7–31
h, respectively, and those of the ions at m/z 512.26845 and
514.28485 increased at 7–55 h compared to the pre-dose
intensities.  The PCA scores plot showed that the
biochemical compositions of the ANIT-treated rat urine
samples at 7–24 h, 24–31 h, 31–48 h and 48–55 h differed
from the pre-dose composition, with the maximum
difference at 24–31 h.  The compositions of the urine
samples at 55–72 h and 72–96 h were almost the same as the
pre-dose composition.  Increased levels of AST and ALT
(serum markers for hepatocyte injury) and ALP and TBIL
(markers for cholestasis) were seen on Day 2.  However,
there were no serum biochemical findings at 24–31 h,
whereas the shift on the PCA scores plot indicated
differences in the urine composition at this time.  Therefore,
these results suggest that urinary metabolic fingerprinting
with FT-ICR MS is more sensitive than traditional serum
biochemistry methods.
The loading plot indicated that the ions at m/z
178.05168, 192.06730, 195.05139, 242.01323, 512.26845
and 514.28485 were potential urinary biomarkers for
intrahepatic cholestasis.  The ions at m/z 178.05168,
192.06730, 242.01323, 512.26845 and 514.28485 were
identified as HA, PAG, 3-methyldioxyindole sulfate,
taurocholic acid (TA) with one double bond, and TA,
respectively.  TA and TA with one double bond are both bile
acids, and an increase in the levels of urinary bile acids is a
well-known feature of intrahepatic cholestasis25.
Histopathologically, cholestasis-induced bile ductar cell
necrosis and subsequent membrane breakdown caused by
ANIT results in elevation of urinary bile acids after 7–55 h.
In previous urinary metabolic fingerprinting in ANIT-
induced intrahepatic cholestasis, changes in PAG have been
found by LC-MS26 and a decrease in urinary HA has been
shown using NMR29, 30.
The levels of 3-methyldioxyindole sulfate, a tryptophan
metabolite, were lower at 0–24 h and higher at 31–55 h, but
the relationship of this metabolite with hepatic toxicity is
unclear.  A decrease of the ion at m/z 242 has been found in
urinary metabolic fingerprinting in ANIT-induced
intrahepatic cholestasis using LC-MS25, and a similar
decrease was observed in rat urine following TAA-induced
hepatic injury.  These results indicate that decrease in urinary
3-methyldioxyindole sulfate may be correlated with
hepatotoxicity.  Further study is required to examine the
relationship between the toxicity of ANIT with potential
Fig. 4. (A) FT-ICR MS spectrum and (B) PCA scores for FT-ICR
MS urinary profiles of thioacetamide-treated rats recorded in
positive ion mode. (A) Pre-dose (a), Day 1 (b), Day 3 (c), Day
5 (d) and Day 7 (e).  The intensity of the ions at m/z
266.05390 on Day 3 increased compared to the pre-dose
levels.  (B) Pre-dose ( ), Day 1 ( ), Day 3 ( ), Day 5 ( ),
Day 7 ( ).  The PCA scores show that the positive ion
compositions of the samples on Days 1 and 3 differed from
the pre-dose composition.  The composition on Day 5 was
similar to the pre-dose composition.Hasegawa, Ide, Kuwamura et al. 73
biomarkers including PAG, HA and 3-methyldioxyindole
sulfate.
Conclusions
A number of metabolomics studies using NMR and/or
MS have been performed to detect metabolic alterations
induced by administration of compounds to assess their
toxicity.  The results shown above indicate that urinary
metabolic fingerprinting with FT-ICR MS can be used to
detect metabolic changes and to identify potential
biomarkers induced by compounds with different
mechanisms of toxicity.  Therefore, metabolomics
approaches including metabolic fingerprinting have the
potential to reveal onset of toxicity at an early stage of drug
development.  To reach this goal, improvements in the
technology for metabolomics are required to allow detection
of the whole metabolome with a high degree of accuracy.
Improved informatics approaches, including database
construction, are also needed for identification of
biomarkers, with follow-up studies to validate biomarker
concentrations in biofluid and metabolic pathways in vivo.
These advances will allow future application of
toxicological assessment in personalized medicine.
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